Skip to main content

MoneyWorks4Me

Glenmark Pharmaceuticals’ arm submits IND application to USFDA for ISB 2301

18 Nov 2026 Evaluate

Glenmark Pharmaceuticals’ biotech arm -- Ichnos Glenmark Innovation, Inc. (IGI) has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (USFDA) for ISB 2301. ISB 2301 is a first-in-class, investigational multispecific immune cell activator designed to target three tumor-associated antigens and engage both T cells and NK cells. This pentaspecific molecule combines five binding specificities: three tumor-associated antigens, plus T-cell and NK-cell activation. By combining tumor-cell recognition with complementary immune activity, ISB 2301 is being developed to address biological heterogeneity and immune-suppressive features of solid tumors.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.

Peers
Company Name CMP
Sun Pharma. Inds. 1872.30
Dr. Reddys Labs. 1396.00
Cipla 1420.00
Lupin 1968.95
Zydus Lifesciences 1195.00
View more..